Investigation Report on China's Daratumumab Markets, 2016-2020 & 2021-2025: Developed by Johnson & Johnson - A Monoclonal Antibody Available for the Treatment of Myeloma -

DUBLIN--()--The "Investigation Report on China's Daratumumab Market 2021-2025" report has been added to's offering.

Daratumumab, developed by Johnson & Johnson, is a monoclonal antibody available for the treatment of myeloma. Its product DARZALEX was approved for the treatment of patients with multiple myeloma who have received at least one therapy, including a proteasome inhibitor and an immunomodulatory agent.

It is the first human anti-CD38 monoclonal antibody (mAb) approved anywhere in the world. Daratumumab was approved in China in 2019, and by the first half of 2021, Janssen-Cilag International NV(BE) is the only manufacturer in the Chinese Daratumumab market.

According to the market research, since Daratumumab entered the Chinese market in 2019, its sales have grown rapidly. The sales of Daratumumab increased from around CNY0.5 million in 2019 to around CNY24.82 million in 2020, with an annual increase of more than 40 times.

The analyst predicts its sales volume will continue to grow from 2021 to 2025 with the expansion of the Daratumumab market. In 2020, Johnson & Johnson has submitted two applications for the approval of Daratumumab in China for new indications. With the increase in the number of indications, its sales volume will continue to grow.

In addition, Daratumumab, a novel human monoclonal antibody, binding CD38, is more effective than bortezomib and lenalidomide. Therefore, the market share of Daratumumab will expand, and sales will continue to rise in the future.

Topics Covered:

  • The impact of COVID-19 on China's Daratumumab market
  • Sales value of China's Daratumumab 2016-2020
  • Competitive landscape of China's Daratumumab market
  • Prices of Daratumumab in China
  • Prices of Daratumumab in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Daratumumab market
  • Prospect of China's Daratumumab market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Daratumumab

1.1 Indications for Daratumumab

1.2 Development of Daratumumab in China

1.3 Governmental Approval of Daratumumab in China

1.4 The Impact of COVID-19 on Daratumumab sales in China

2 Sales of Daratumumab in China, 2018-2020

2.1 Sales Value of Daratumumab

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Daratumumab

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Daratumumab by Dosage Form in China, 2018-2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Daratumumab Manufacturers in China, 2018-2020

3.1 Analysis of Market Share of Major Daratumumab Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Janssen-Cilag International NV(BE)

3.2.1 Enterprise Profile

3.2.2 Sales of DARZALEX (Janssen-Cilag International NV(BE)'s Daratumumab) in China

4 Prices of Daratumumab for Different Manufacturers in China, 2020-2021

4.1 Janssen-Cilag International NV(BE) (DARZALEX)

4.2 Analysis of Other Enterprises

5 Prospect of Chinese Daratumumab drug Market, 2021-2025

5.1 Influential Factors of Chinese Daratumumab Market Development

5.1.1 The Impact of COVID-19 on Chinese Daratumumab Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900